Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Clarification; each of the passages should have been bulleted to indicate they came from different sections of the paper. Also, the first paragraph/bullet was pasted because I thought interesting that NCCN now recommends standard molecular profiling to detect mutations for NSCLC. So that becomes part of Std of Care making it easier to determine if a patient should get what drug. That was one of the concerns w LOXO's Vitrakvi for patients with advanced solid tumors containing what’s called an NTRK gene fusion. Those tests weren't standard when Bayer bought rights to the drug. They might be now.